Personalised Cancer Care – Where are we now?Personalised cancer care has made significant strides in recent years, with a growing emphasis on tailoring treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. From personalised care leveraging genomics to making care truly personal and person-centred, these advancements are reshaping the landscape of … Read more
Targeted therapies for high-risk cancer – a reason for hope?Targeted therapies for high-risk cancers use drugs or substances to specifically attack cancer cells or environments based on their genetic mutations, minimising damage to healthy cells. These therapies may offer a more personalised and effective treatment approach. Join us for an insightful session where leading experts … Read more
Molecular Tumour Board. Treating Acute Myeloid Leukaemia in the Genomics EraSpeakersDr Lachlin Vaughan. Clinical and laboratory haematologist and the clinical lead for acute leukaemias at Westmead Hospital.Dr Gaurav Sutrave. Staff Specialist Haematologist and a Blood Transplant and Cell Therapies Physician at Westmead Hospital, and the Medical Director for the Westmead T cell Therapies Laboratory.
The Single Patient Digital Record (SPDR) project and how this may help support clinical and basic science research. The NSW Health Single Patient Digital Record (SPDR) project is creating a comprehensive digital record for each NSW Health patient, integrating data from various healthcare sources. As well as optimizing access to vital patient information for clinicians … Read more
Cancer Prevention Research in Specific PopulationsImproving health outcomes for Aboriginal and Torres Strait Island communities and other specific populations requires culturally responsive cancer prevention, early detection, and treatment strategies. This seminar provides insights from two cancer prevention studies undertaken: “Culturally Responsive Approaches to Smoking and Vaping Cessation” and “Understanding Youth Perspectives: Cervical Cancer Prevention among … Read more
Molecular Tumour Board. The biomarker boom in non-squamous, non-small cell lung cancer. Efficient testing and personalised treatment.Three cases will be presented exemplifying the standard of care for molecular testing in NSCLC, and impact this may have on the therapeutic pathway and survival. Cases may have accessed liquid biopsy to expedite diagnosis, monitor disease control and/or … Read more
Harnessing Digital Health for Enhanced Cancer research and Patient OutcomesDigital health technologies – such as platforms for telemedicine, patient education, health monitoring, and data management – offer transformative potential for cancer research and care. Digital health tools facilitate real-time patient monitoring, improve access to care, and support data-driven decision making. By integrating digital health into … Read more
Appendiceal neoplasms: shedding light on a rare diseaseAppendiceal neoplasms are rare, poorly researched and have a wide range of outcomes. This seminar will discuss the varied subtypes of disease, current treatment options and our research program that aims to better understand the biology, develop useful tumour models and ultimately define new therapeutics. SpeakersA/Prof Kate Mahon. … Read more
Early-onset bowel cancer – detection & treatment gains amid the biggest cancer killer in the under-50sA diagnosis of colorectal cancer is always life-changing, but it is particularly devastating in the under-50s. This seminar will discuss the rising incidence of early colorectal cancer; the evolution of screening recommendations; the utility of advanced surgical options and real-world … Read more
Educational Molecular Tumour Board.The potential role of precision medicine in altering the poor outcomes in pancreas cancer.Pancreatic cancer has a poor prognosis and an urgent need for new effective treatments. In this educational Molecular Tumour Board session, we will hear an update on the molecular features of pancreatic cancer and their relevance to clinical management. … Read more
